Suchergebnisse

This book engages the Chester Beatty Biblical Papyri, one of the most important collections of early manuscripts of Jewish scripture and the New Testament, by placing them within larger conversations relating to ancient literature and its interpretation, papyrology, and the ethics of collecting and scholarship. Ninety years after Beatty acquired these manuscripts, their value for scholarship and culture remains largely unexplored.

BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of visual loss in older people. Advanced AMD takes two forms, neovascular (wet) and atrophic (dry). Stargardt disease (STGD) is the commonest form of inherited macular dystrophy. OBJECTIVE: To carry out a systematic review of treatments for dry AMD and STGD, and to identify emerging treatments where future NIHR research might be commissioned. DESIGN: Systematic review. METHODS: We searched MEDLINE, EMBASE, Web of Science and The Cochrane Library from 2005 to 13 July 2017 for reviews, journal articles and meeting abstracts. We looked for studies of interventions that aim to preserve or restore vision in people with dry AMD or STGD. The most important outcomes are those that matter to patients: visual acuity (VA), contrast sensitivity, reading speed, ability to drive, adverse effects of treatment, quality of life, progression of disease and patient preference. However, visual loss is a late event and intermediate predictors of future decline were accepted if there was good evidence that they are strong predictors of subsequent visual outcomes. These include changes detectable by investigation, but not necessarily noticed by people with AMD or STGD. ClinicalTrials.gov, the World Health Organization search portal and the UK Clinical Trials gateway were searched for ongoing and recently completed clinical trials. RESULTS: The titles and abstracts of 7948 articles were screened for inclusion. The full text of 398 articles were obtained for further screening and checking of references and 112 articles were included in the final report. Overall, there were disappointingly few good-quality studies (including of sufficient size and duration) reporting useful outcomes, particularly in STGD. However we did identify a number of promising research topics, including drug treatments, stem cells, new forms of laser treatment, and implantable intraocular lens telescopes. In many cases, research is already under way, funded by industry or governments. LIMITATIONS: In AMD, the main limitation came from the poor quality of much of the evidence. Many studies used VA as their main outcome despite not having sufficient duration to observe changes. The evidence on treatments for STGD is sparse. Most studies tested interventions with no comparison group, were far too short term, and the quality of some studies was poor. FUTURE WORK: We think that the topics on which the Health Technology Assessment (HTA) and Efficacy Mechanism and Evaluation (EME) programmes might consider commissioning primary research are in STGD, a HTA trial of fenretinide (ReVision Therapeutics, San Diego, CA, USA), a visual cycle inhibitor, and EME research into the value of lutein and zeaxanthin supplements, using short-term measures of retinal function. In AMD, we suggest trials of fenretinide and of a potent statin. There is epidemiological evidence from the USA that the drug, levodopa, used for treating Parkinson's disease, may reduce the incidence of AMD. We suggest that similar research should be carried out using the large general practice databases in the UK. Ideally, future research should be at earlier stages in both diseases, before vision is impaired, using sensitive measures of macular function. This may require early detection of AMD by screening.

The predicted emergence of cancer as a major NCD in developing countries by 2020 has already prompted some governments to invest in cancer treatment. The large medical devices required to provide comprehensive radiotherapy are both expensive to purchase and to install. Manufacturers have therefore started producing a range of large medical devices which are specifically designed for the emerging market in developing countries. This market, however, can produce unforeseen problems. The lack of experience of the logistics involved in the delivery and installation of such large pieces of equipment can often lead to underestimations in time scales by the recipients. Advice and assistance on the clinical procurement process is essential for avoiding long delays. Within the UK, the lifecycle of radiotherapy machines can often be ten years or less, which in most cases is well below the actual lifetime of the machines. Therefore many machines are decommissioned to be scrapped well within the usable equipment lifetime. However, if decommissioning was performed so that the machine could be salvaged, the extra cost would be relatively low. Such machines could be serviced and donated to developing countries allowing them to increase their radiotherapy coverage greatly for the cost of the decommissioning, servicing and installation process. Therefore it would seem that with a small change to the decommissioning process of large medical devices, developing countries who could benefit from equipment, which otherwise would be scrapped, could attain a large number of life changing pieces of equipment within their tight budgetary constraints and make a real impact on the predicted increase in cancer deaths.

Camera trapping surveys frequently capture individuals whose identity is only known from a single flank. The most widely used methods for incorporating these partial identity individuals into density analyses discard some of the partial identity capture histories, reducing precision, and, while not previously recognized, introducing bias. Here, we present the spatial partial identity model (SPIM), which uses the spatial location where partial identity samples are captured to probabilistically resolve their complete identities, allowing all partial identity samples to be used in the analysis. We show that the SPIM outperforms other analytical alternatives. We then apply the SPIM to an ocelot data set collected on a trapping array with double-camera stations and a bobcat data set collected on a trapping array with single-camera stations. The SPIM improves inference in both cases and, in the ocelot example, individual sex is determined from photographs used to further resolve partial identities-one of which is resolved to near certainty. The SPIM opens the door for the investigation of trapping designs that deviate from the standard two camera design, the combination of other data types between which identities cannot be deterministically linked, and can be extended to the problem of partial genotypes. ; Public domain authored by a U.S. government employee

OBJECTIVE: To summarise studies describing incidence of sudden cardiac death in a general population of young individuals to inform screening policy. DESIGN: Systematic review. DATA SOURCES: Database searches of MEDLINE, EMBASE and the Cochrane library (all inception to current) on 29 April 2019 (updated 16 November 2019), and forward/backward citation tracking of eligible studies. STUDY ELIGIBILITY CRITERIA: All studies that reported incidence of sudden cardiac death in young individuals (12–39 years) in a general population, with no restriction on language or date. Planned subgroups were incidence by age, sex, race and athletic status (including military personnel). DATA EXTRACTION: Two reviewers independently assessed study eligibility, extracted study data and assessed risk of bias using the Joanna Briggs Institute critical appraisal checklist for prevalence studies. ANALYSIS: Reported incidence of sudden cardiac death in the young per 100 000 person-years. RESULTS: 38 studies that reported incidence across five continents. We identified substantial heterogeneity in population, sudden cardiac death definition, and case ascertainment methods, precluding meta-analysis. Median reported follow-up years was 6.97 million (IQR 2.34 million–23.70 million) and number of sudden cardiac death cases was 64 (IQR 40–251). In the general population, the median of reported incidence was 1.7 sudden cardiac death per 100 000 person-years (IQR 1.3–2.6, range 0.75–11.9). Most studies (n=14, 54%) reported an incidence between one and two cases per 100 000 person-years. Incidence was higher in males and older individuals. CONCLUSIONS: This systematic review identified variability in the reported incidence of sudden cardiac death in the young across studies. Most studies reported an incidence between one and two cases per 100 000 person-years. PROSPERO REGISTRATION NUMBER: CRD42019120563.

Frontmatter -- Contents -- Acknowledgements -- Notes on Contributors -- Introduction: The Animal Question in Deconstruction -- 1. A Refugee -- 2. Swans of Life (External Provocations and Autobiographical Flights That Teach Us How to Read) -- 3. Love of the Löwe -- 4. Insect Asides -- 5. Sponge Inc -- 6. Elephant Eulogy: The Exorbitant Orb of an Elephant -- 7. Troubling Resemblances, Anthropological Machines and the Fear of Wild Animals: Following Derrida after Agamben -- 8. Derrida, Rousseau, Cixous and Tsvetaeva: Sexual Difference and the Love of the Wolf -- 9. Deconstructing Sexual Difference: A Myopic Reading of Hélène Cixous's Mole -- 10. Your Worm -- 11. Mole -- Index

Frontmatter -- CONTENTS -- PREFACE -- Introduction TARTAN, TARTANRY AND HYBRIDITY -- 1 GHEIBHTE BREACAIN CHARNAID ('SCARLET TARTANS WOULD BE GOT . . .'): THE RE-INVENTION OF TRADITION -- 2 PLAIDING THE INVENTION OF SCOTLAND -- 3 FROM DAVID STEWART TO ANDY STEWART: THE INVENTION AND RE-INVENTION OF THE SCOTTISH SOLDIER -- 4 PAYING FOR THE PLAID: SCOTTISH GAELIC IDENTITY POLITICS IN NINETEENTHCENTURY NORTH AMERICA -- 5 TARTANRY INTO TARTAN: HERITAGE, TOURISM AND MATERIAL CULTURE -- 6 MYTH, POLITICAL CARICATURE AND MONSTERING THE TARTAN -- 7 TARTANRY AND ITS DISCONTENTS: THE IDEA OF POPULAR SCOTTISHNESS -- 8 'WHA'S LIKE US?': ETHNIC REPRESENTATION IN MUSIC HALL AND POPULAR THEATRE AND THE REMAKING OF URBAN SCOTTISH SOCIETY -- 9 LITERARY TARTANRY AS TRANSLATION -- 10 LOOKING AT TARTAN IN FILM: HISTORY, IDENTITY AND SPECTACLE -- 11 TARTAN COMICS AND COMIC TARTANRY -- 12 ROCK, POP AND TARTAN -- 13 CLASS WARRIORS OR GENEROUS MEN IN SKIRTS? THE TARTAN ARMY IN THE SCOTTISH AND FOREIGN PRESS -- 14 DON'T TAKE THE HIGH ROAD: TARTANRY AND ITS CRITICS -- BIBLIOGRAPHY -- NOTES ON THE CONTRIBUTORS -- INDEX

This unique book brings together, for the first time, advocates and critics of the personalisation agenda in English social care services to debate key issues relating to personalisation. Perspectives from service users, practitioners, academics and policy commentators come together to give an account of the practicalities and controversies associated with the implementation of personalised approaches. The conclusion examines how to make sense of the divergent accounts presented, asking if there is a value-based approach to person-centred care that all sides share. Written in a lively and accessible way, practitioners, students, policy makers and academics in health and social care, social work, public policy and social policy will appreciate the interplay of rival arguments and the way that ambiguities in the care debate play out as policy ideas take programmatic form

Structural brain magnetic resonance imaging (MRI) traits share part of their genetic variance with cognitive traits. Here, we use genetic association results from large meta-analytic studies of genome-wide association (GWA) for brain infarcts (BI), white matter hyperintensities, intracranial, hippocampal, and total brain volumes to estimate polygenic scores for these traits in three Scottish samples: Generation Scotland: Scottish Family Health Study (GS:SFHS), and the Lothian Birth Cohorts of 1936 (LBC1936) and 1921 (LBC1921). These five brain MRI trait polygenic scores were then used to: (1) predict corresponding MRI traits in the LBC1936 (numbers ranged 573 to 630 across traits), and (2) predict cognitive traits in all three cohorts (in 8,115–8,250 persons). In the LBC1936, all MRI phenotypic traits were correlated with at least one cognitive measure, and polygenic prediction of MRI traits was observed for intracranial volume. Meta-analysis of the correlations between MRI polygenic scores and cognitive traits revealed a significant negative correlation (maximal r = 0.08) between the HV polygenic score and measures of global cognitive ability collected in childhood and in old age in the Lothian Birth Cohorts. The lack of association to a related general cognitive measure when including the GS:SFHS points to either type 1 error or the importance of using prediction samples that closely match the demographics of the GWA samples from which prediction is based. Ideally, these analyses should be repeated in larger samples with data on both MRI and cognition, and using MRI GWA results from even larger meta-analysis studies.

Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.

Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.